Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Heshaam M. Mir"'
Autor:
Mark S. Sulkowski, Nezam H. Afdhal, John McNally, David L. Wyles, Jordan J. Feld, Jason Grebely, Heshaam M Mir, Stefan Zeuzem, Liyun Ni, Robert H. Hyland, Marc Bourlière, Diana M. Brainard, Joe Llewellyn, Ira M. Jacobson, Gregory J. Dore, Nika Sajed, Graham R. Foster, Luisa M. Stamm
Publikováno v:
Open Forum Infectious Diseases
Background Hepatitis C virus (HCV) direct-acting antiviral therapy is effective among people receiving opioid substitution therapy (OST), but studies are limited by small numbers of nongenotype 1 (GT1) patients. The aim of this study was to evaluate
Publikováno v:
Journal of Clinical and Experimental Hepatology. 3:181-185
Nonalcoholic fatty liver disease (NAFLD) is a major cause of chronic liver disease. In smaller studies, sleep apnea has been previously associated with NAFLD. The aim of this study was to assess the prevalence and independent associations of sleep di
Autor:
Heshaam M. Mir, Zobair M. Younossi, Alita Mishra, Gregory Trimble, Shirley Kalwaney, L. Zheng
Publikováno v:
Alimentary Pharmacology & Therapeutics. 38:596-602
Summary Background Excessive alcohol use has been reported to be responsible for 80 000 annual deaths in the United States. However, the exact cause of death related to the excessive use of alcohol has not been fully explored. Aim To assess the effec
Publikováno v:
Clinics in Liver Disease. 13:477-486
The potential for developing efficient and efficacious therapies for hepatitis C virus continues to improve. Insight into the molecular processes involved in attachment, entry, and fusion suggests that antibodies could potentially inhibit viral repli
Autor:
Anita Kohli, Edward Gane, Heshaam M. Mir, Tarik Asselah, Macky Natha, John G. McHutchison, Robert H. Hyland, Kathryn Kersey, Catherine A.M. Stedman, Phil Pang, Armand Abergel
Publikováno v:
American Journal of Gastroenterology. 110:S870-S871
Publikováno v:
Journal of hepatology. 60(3)
Background & Aims Hepatitis C (HCV) is a common cause of chronic liver disease worldwide. Current standard treatment for genotype-1 patients uses a triple combination of pegylated-interferon alpha (IFN), ribavirin (RBV) and a direct-acting antiviral
Publikováno v:
Value in Health. 16(3)
Publikováno v:
Alimentary pharmacologytherapeutics. 37(7)
Summary Background The impact of moderate alcohol consumption on long-term outcomes of chronic hepatitis C (CH-C) infected patients remains controversial. Aim To assess the impact of moderate alcohol consumption on long-term outcomes of CH-C patients
Publikováno v:
Psychosomatics. 54(1)
Objective Chronic liver diseases (CLD) have been associated with depression. Our aim was to assess the association of different types of CLD with depression in a population-based cohort. Methods We examined data from National Health and Nutrition Exa
Publikováno v:
Journal of clinical gastroenterology. 46(8)
BACKGROUND: Hepatitis C virus (HCV) is the most common cause of chronic liver disease in the United States. African Americans are known to have a higher prevalence of HCV and lower response to anti-HCV therapy. GOAL: The aim of this study is to asses